I refer to the clinical-data table in the PR linked in #msg-96615816. Evidently, ribavirin is not needed for GT1b patients, either treatment-naive, or treatment-experienced, but its is needed for GT1a patients. This is a strong outcome for ABBV/ENTA insofar as GILD’s ION-2 data in treatment-experienced patients (#msg-95103023) suggest that ribavirin will be needed for a 12w regimen in GT1a patients and possibly also in GT1b patients. (GILD has not broken down the ION-2 data by genotype subtype.)
Moreover, ABBV/ENTA’s SVR12 rates results from TURQUOISE-2 in cirrhotic patients—especially the 96% rate in the 24w arm—are better than anyone could have expected.
Bottom line: ABBV/ENTA’s overall phase-3 package (SAPHIRE-1, SAPHIRE-2, PEARL-2, PEARL-3, PEARL-4, and TURQUOISE-2) is an extremely compelling package that can easily hold its own again GILD’s ‘ION’ studies (#msg-95103023).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.